Pozuelo De Alarcon

• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w … Ended
  2022-501451-87-00 9 2023-03-31 Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 Metastatic melanoma
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after … Ended
  2024-510980-40-00 3 2023-03-09 Small cell lung cancer
• Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2 … Ended
  2024-512590-27-00 9 2023-03-08 Non-resectable locally advanced or metastatic HER2-positive breast can
• A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi … Ended
  2022-500594-13-00 4 2022-12-14 "Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-A
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S … Ended
  2024-511610-20-00 4 2022-11-08 Alzheimer's Disease
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended
  2023-508404-37-00 3 2022-10-26 Non-muscle Invasive Bladder Cancer
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended
  2022-500287-35-00 3 2022-09-21 Metastatic or Locally Advanced Unresectable Solid Tumors
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 Unresectable Locally Advanced or Metastatic Cancer
• A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C … Ended
  2024-514532-24-00 3 2022-06-23 Solid cancer tumors
• To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo … Ended
  2024-510644-31-00 3 2022-06-10 Relapsed/Refractory Multiple Myeloma
• A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with … Ended
  2022-502752-31-00 11 2022-04-29 Non-small cell lung cancer
• A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patien … Ended
  2024-513229-22-00 4 2022-04-21 Advanced cutaneous melanoma and Advanced mucosal melanoma
• "OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T … Ended
  2023-505097-16-00 4 2022-04-04 Ovarian Neoplasms
• A Phase 2 Trial of SCO-101 in combination with FOLFIRI for Patients with Metastatic Colorectal Cancer (mCRC) with acquired Resistance to FOL … Ended
  2024-518877-33-00 4 2022-03-17 Metastatic Colorectal Cancer
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administ … Ended
  2024-514777-22-00 1 2022-02-07 Advanced Malignancies
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20 Chronic Obstructive Pulmonary Disease (COPD)
• GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended
  2024-510722-10-00 7 2021-12-13 Malignant Solid Tumors
• Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended
  2022-500752-39-00 5 2021-11-25 Prevention of Respiratory syncytial virus (RSV) infection in infants a
• A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended
  2024-511999-32-00 9 2021-11-19 Advanced/Metastatic EGFR-expressing Cancers

Showing 289–312 of 344 trials